Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 7/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.41 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2424263 | 1.00 | SLC7A5 (0.46) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| SCHEMBL25660322 | 0.85 | SLC7A5 (0.46) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| SCHEMBL25660924 | 0.85 | SLC7A5 (0.46) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| SCHEMBL197117 | 0.82 | SLC7A5 (0.48) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| SCHEMBL196695 | 0.82 | SLC7A5 (0.48) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| SCHEMBL197139 | 0.82 | SLC7A5 (0.48) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| SCHEMBL31215074 | 0.80 | SLC7A5 (0.46) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Hydrochloric Acid SCHEMBL18770586 | 0.80 | SLC7A5 (0.46) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Ammonia Solution, Strong SCHEMBL28728215 | 0.80 | SLC7A5 (0.46) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| SCHEMBL935820 | 0.80 | SLC7A5 (0.46) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARM INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12427130-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12378263-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3615019-B1 | MODULATOR OF SESTRIN-GATOR2 INTERACTION FOR USE IN THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION | NAVITOR PHARM INC (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4556069-A2 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20240091184-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2024-03-21 | — | — | US | disclosed |
| CN-116370448-A | Modulators of SESTRIN-GATOR2 interactions and uses thereof | 纳维托制药有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| WO-2017070518-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017070518-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2017-04-27 | — | — | US | disclosed |
| US-8765910-B2 | Method for amidating polypeptides with basic amino acid C-terminals by means of specific endoproteases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| EP-1931705-B1 | METHOD FOR AMIDATING POLYPEPTIDES WITH BASIC AMINOACID C- TERMINALS BY MEANS OF SPECIFIC ENDOPROTEASES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-09-07 | — | — | EP | disclosed |
| US-20100311112-A1 | METHOD FOR AMIDATING POLYPEPTIDES WITH BASIC AMINO ACID C-TERMINALS BY MEANS OF SPECIFIC ENDOPROTEASES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-12-09 | — | — | US | disclosed |
| EP-1931705-A2 | METHOD FOR AMIDATING POLYPEPTIDES WITH BASIC AMINOACID C- TERMINALS BY MEANS OF SPECIFIC ENDOPROTEASES | Sanofi-Aventis Deutschland GmbH (DE) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007036299-A2 | METHOD FOR AMIDATING POLYPEPTIDES WITH BASIC AMINOACID C- TERMINALS BY MEANS OF SPECIFIC ENDOPROTEASES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-05 | — | — | WO | disclosed |
| US-4206283-A | PROCIDINS PRODUCED BY STREPTOMYCES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1980-06-03 | — | — | US | disclosed |
| US-4091093-A | ANTIULCER PROCIDIN PRODUCED BY STREPTOMYCES PROCIDINANUS | SUMITOMO CHEMICAL COMPANY LIMITED (JA) | 1978-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | RICTOR, RPTOR, MTOR | SLC7A5 374/4885PTGS1 3842/4885SLC7A11 1221/4885 |
| US-20240091184-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | SLC7A5 2349/4885PTGS1 4308/4885SLC7A11 737/4885 |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | SLC7A5 2349/4885PTGS1 4308/4885SLC7A11 737/4885 |
| US-12378263-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | SLC7A5 2349/4885PTGS1 4308/4885SLC7A11 737/4885 |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | SLC7A5 2349/4885PTGS1 4308/4885SLC7A11 737/4885 |
| US-12427130-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | SLC7A5 2349/4885PTGS1 4308/4885SLC7A11 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.